- Home
- KF vs CLYM Comparison
KF vs CLYM Comparison
Compare KF & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- CLYM
- Stock Information
- Founded
- KF 1984
- CLYM 2018
- Country
- KF United States
- CLYM United States
- Employees
- KF N/A
- CLYM N/A
- Industry
- KF Investment Managers
- CLYM
- Sector
- KF Finance
- CLYM
- Exchange
- KF Nasdaq
- CLYM NYSE
- Market Cap
- KF 94.9M
- CLYM 101.6M
- IPO Year
- KF N/A
- CLYM 2021
- Fundamental
- Price
- KF $21.21
- CLYM $1.47
- Analyst Decision
- KF
- CLYM
- Analyst Count
- KF 0
- CLYM 0
- Target Price
- KF N/A
- CLYM N/A
- AVG Volume (30 Days)
- KF 18.4K
- CLYM 331.6K
- Earning Date
- KF 01-01-0001
- CLYM 03-27-2025
- Dividend Yield
- KF N/A
- CLYM N/A
- EPS Growth
- KF N/A
- CLYM N/A
- EPS
- KF N/A
- CLYM N/A
- Revenue
- KF N/A
- CLYM N/A
- Revenue This Year
- KF N/A
- CLYM N/A
- Revenue Next Year
- KF N/A
- CLYM N/A
- P/E Ratio
- KF N/A
- CLYM N/A
- Revenue Growth
- KF N/A
- CLYM N/A
- 52 Week Low
- KF $18.30
- CLYM $1.41
- 52 Week High
- KF $25.56
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- KF 67.78
- CLYM N/A
- Support Level
- KF $19.86
- CLYM N/A
- Resistance Level
- KF $21.49
- CLYM N/A
- Average True Range (ATR)
- KF 0.25
- CLYM 0.00
- MACD
- KF 0.14
- CLYM 0.00
- Stochastic Oscillator
- KF 87.67
- CLYM 0.00
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.